STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD. Financials Staidson (Beijing) BioPharmaceuticals Co., Ltd.
Equities
300204
CNE100001237
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.77 CNY | -4.38% |
|
+1.35% | -33.37% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,282 | 5,223 | 4,241 | 8,242 | 6,419 | 4,854 |
| Enterprise Value (EV) 1 | 4,436 | 4,433 | 3,566 | 7,784 | 6,160 | 4,810 |
| P/E ratio | 39.6 x | 185 x | -32.3 x | -60.5 x | -33.2 x | -12.1 x |
| Yield | 5.96% | - | - | - | - | - |
| Capitalization / Revenue | 6.55 x | 7.9 x | 9.97 x | 14.1 x | 11.7 x | 13.3 x |
| EV / Revenue | 5.5 x | 6.7 x | 8.39 x | 13.3 x | 11.2 x | 13.2 x |
| EV / EBITDA | 40.1 x | 946 x | -23 x | -37.8 x | -30.4 x | -14 x |
| EV / FCF | 14.6 x | 11.8 x | -38.3 x | -51.8 x | -37 x | -30.2 x |
| FCF Yield | 6.86% | 8.47% | -2.61% | -1.93% | -2.7% | -3.31% |
| Price to Book | 2.15 x | 3.19 x | 2.67 x | 5.35 x | 4.78 x | 4.76 x |
| Nbr of stocks (in thousands) | 476,705 | 469,653 | 469,653 | 469,653 | 471,988 | 477,773 |
| Reference price 2 | 11.08 | 11.12 | 9.030 | 17.55 | 13.60 | 10.16 |
| Announcement Date | 3/4/19 | 3/16/20 | 4/19/21 | 4/18/22 | 3/20/23 | 3/25/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 806.1 | 661.5 | 425.2 | 584.3 | 549 | 364.2 |
| EBITDA 1 | 110.8 | 4.685 | -155.2 | -205.9 | -202.7 | -342.7 |
| EBIT 1 | 84.12 | -25.48 | -189.8 | -239.5 | -233.7 | -373.6 |
| Operating Margin | 10.44% | -3.85% | -44.64% | -40.99% | -42.57% | -102.6% |
| Earnings before Tax (EBT) 1 | 151 | 20.15 | -160.2 | -213 | -243.1 | -366.4 |
| Net income 1 | 134.1 | 27.3 | -133 | -137.4 | -197 | -398.9 |
| Net margin | 16.63% | 4.13% | -31.28% | -23.52% | -35.89% | -109.53% |
| EPS 2 | 0.2800 | 0.0600 | -0.2800 | -0.2900 | -0.4100 | -0.8400 |
| Free Cash Flow 1 | 304.2 | 375.2 | -93.04 | -150.3 | -166.6 | -159.2 |
| FCF margin | 37.74% | 56.73% | -21.88% | -25.72% | -30.34% | -43.72% |
| FCF Conversion (EBITDA) | 274.66% | 8,008.62% | - | - | - | - |
| FCF Conversion (Net income) | 226.91% | 1,374.52% | - | - | - | - |
| Dividend per Share 2 | 0.6600 | - | - | - | - | - |
| Announcement Date | 3/4/19 | 3/16/20 | 4/19/21 | 4/18/22 | 3/20/23 | 3/25/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 846 | 790 | 675 | 459 | 259 | 44.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 304 | 375 | -93 | -150 | -167 | -159 |
| ROE (net income / shareholders' equity) | 5.74% | 1.33% | -8.26% | -8.76% | -13.6% | -33.6% |
| ROA (Net income/ Total Assets) | 1.95% | -0.69% | -6.38% | -8.13% | -8.36% | -15.6% |
| Assets 1 | 6,886 | -3,973 | 2,085 | 1,690 | 2,358 | 2,563 |
| Book Value Per Share 2 | 5.160 | 3.480 | 3.380 | 3.280 | 2.850 | 2.140 |
| Cash Flow per Share 2 | 0.7700 | 0.7500 | 0.3000 | 0.1800 | 0.5600 | 0.1800 |
| Capex 1 | 95.5 | 59.9 | 48.9 | 56.2 | 56.5 | 32.2 |
| Capex / Sales | 11.84% | 9.06% | 11.49% | 9.62% | 10.29% | 8.83% |
| Announcement Date | 3/4/19 | 3/16/20 | 4/19/21 | 4/18/22 | 3/20/23 | 3/25/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -33.37% | 468M | |
| -2.61% | 88.47B | |
| +3.55% | 40.71B | |
| -14.07% | 32.43B | |
| +55.89% | 24.28B | |
| -16.16% | 15.52B | |
| -41.29% | 12.17B | |
| -15.43% | 12.01B | |
| -11.75% | 12B | |
| +7.87% | 8.87B |
- Stock Market
- Equities
- 300204 Stock
- Financials Staidson (Beijing) BioPharmaceuticals Co., Ltd.